UOC
RLAY icon

UBS O'Connor’s Relay Therapeutics RLAY Stock Holding History

UBS O'Connor’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-127,036
Closed -$440K – 423
2025
Q2 		$440K Sell
127,036
-255,864
-67% -$761K 0.01% 277
2025
Q1 		$1M Buy
382,900
+52,201
+16% +$205K 0.02% 188
2024
Q4 		$1.36M Buy
330,699
+218,651
+195% +$1.19M 0.03% 206
2024
Q3 		$793K Buy
+112,048
New +$837K 0.02% 301
2024
Q2 		– Sell
-100,039
Closed -$830K – 627
2024
Q1 		$830K Sell
100,039
-33,694
-25% -$329K 0.02% 294
2023
Q4 		$1.47M Sell
133,733
-13,113
-9% -$111K 0.05% 220
2023
Q3 		$1.23M Buy
146,846
+50,461
+52% +$543K 0.02% 307
2023
Q2 		$1.21M Buy
96,385
+52,285
+119% +$650K 0.03% 365
2023
Q1 		$726K Sell
44,100
-12,900
-23% -$231K 0.02% 434
2022
Q4 		$852K Buy
+57,000
New +$1.09M 0.02% 577

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

UBS O'Connor's RLAY Position: Q3 2025 in Review

UBS O'Connor sold out of Relay Therapeutics (RLAY) in Q3 2025, closing a stake of 127,036 shares — an estimated $440K sold.

UBS O'Connor first reported a position in RLAY in Q4 2022 and held it in 10 quarters. The position peaked at $1.47M in Q4 2023. 199 funds tracked by Wall St. Rank hold RLAY as of Q3 2025.

  • UBS O'Connor reported no remaining Relay Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 127,036 Relay Therapeutics shares in Q3 2025, an estimated $440K.
  • UBS O'Connor first reported a position in Relay Therapeutics in Q4 2022 and held it in 10 quarters.
  • UBS O'Connor's Relay Therapeutics position peaked at $1.47M in Q4 2023.
  • 199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.